These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 36299588)

  • 1. Overexpression of
    Yang P; Liu H; Li Y; Gao Q; Chen X; Chang J; Li Y; Chen S; Dong R; Wu H; Liu C; Liu G
    Front Genet; 2022; 13():959832. PubMed ID: 36299588
    [No Abstract]   [Full Text] [Related]  

  • 2. Overexpression of NOP58 as a Prognostic Marker in Hepatocellular Carcinoma: A TCGA Data-Based Analysis.
    Wang J; Huang R; Huang Y; Chen Y; Chen F
    Adv Ther; 2021 Jun; 38(6):3342-3361. PubMed ID: 34014550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.
    Su J; Huang Y; Wang Y; Li R; Deng W; Zhang H; Xiong H
    Cancer Cell Int; 2022 Feb; 22(1):67. PubMed ID: 35139863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma.
    Qin Z; Xie B; Qian J; Ma X; Zhang L; Wei J; Wang Z; Fan L; Zhu Z; Qian Z; Yin H; Zhu F; Tan Y
    Front Oncol; 2023; 13():1144269. PubMed ID: 37056349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma.
    Wang Q; Yu X; Zheng Z; Chen F; Yang N; Zhou Y
    PeerJ; 2021; 9():e11342. PubMed ID: 33987018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC3-Related Genes May Aid in the Prognostic and Immunotherapeutic Analysis of Hepatocellular Carcinoma.
    Yang C; Chen Y; Tao T; Xu P; Li M; Deng B; Lu S; Yang M; Wang W; Wang J; Liu S
    Comb Chem High Throughput Screen; 2024 Jun; ():. PubMed ID: 38859773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
    Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased CDCA2 Level Was Related to Poor Prognosis in Hepatocellular Carcinoma and Associated With Up-Regulation of Immune Checkpoints.
    Tang M; Liao M; Ai X; He G
    Front Med (Lausanne); 2021; 8():773724. PubMed ID: 35372372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
    Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
    Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
    [No Abstract]   [Full Text] [Related]  

  • 11. High expression of TBRG4 in relation to unfavorable outcome and cell ferroptosis in hepatocellular carcinoma.
    Tao S; Cui D; Cheng H; Liu X; Jiang Z; Chen H; Gao Y
    BMC Cancer; 2024 Feb; 24(1):194. PubMed ID: 38347489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of prognostic value and immunological roles of RAB22A in hepatocellular carcinoma.
    Wen F; Meng F; Li X; Li Q; Liu J; Zhang R; Zhao Y; Zhang Y; Wang X; Ju S; Cui Y; Lu Z
    Front Immunol; 2023; 14():1086342. PubMed ID: 36936971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Biological Function of POLA2 in Hepatocellular Carcinoma.
    Yang Z; Shen X; Wang Z; Li R; Hou W; Liu Z; Gao Y; Zhu C; Qin X
    Comb Chem High Throughput Screen; 2024; 27(12):1758-1775. PubMed ID: 37861044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RBM39 is a potential prognostic biomarker with functional significance in hepatocellular carcinoma.
    Cui F; Wang W; Zhuang C; He D; Wang P
    Transl Cancer Res; 2024 Apr; 13(4):1606-1622. PubMed ID: 38737697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of Cyclin F in liver cancer predicts poor prognosis: A study based on TCGA database.
    Zelong Y; Han Y; Ting G; Yifei W; Kun H; Haoran H; Yong C
    Medicine (Baltimore); 2021 Aug; 100(31):e26623. PubMed ID: 34397798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated Small Nuclear Ribonucleoprotein Polypeptide an Expression Correlated With Poor Prognosis and Immune Infiltrates in Patients With Hepatocellular Carcinoma.
    Zhang Y; Wang X; Wang H; Jiang Y; Xu Z; Luo L
    Front Oncol; 2022; 12():893107. PubMed ID: 35860579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDC25B Is a Prognostic Biomarker Associated With Immune Infiltration and Drug Sensitivity in Hepatocellular Carcinoma.
    Huang Z; Xu L; Wu Z; Xiong X; Luo L; Wen Z
    Int J Genomics; 2024; 2024():8922878. PubMed ID: 39371450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma.
    Li HY; Jing YM; Shen X; Tang MY; Shen HH; Li XW; Wang ZS; Su F
    World J Gastrointest Oncol; 2024 Sep; 16(9):3913-3931. PubMed ID: 39350977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AP4M1 as a prognostic biomarker associated with cell proliferation, migration and immune regulation in hepatocellular carcinoma.
    Peng Y; Li X; Kang K; Zhou Y
    Cancer Cell Int; 2023 Oct; 23(1):235. PubMed ID: 37821948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal Expression of Centromere Protein U Is Associated with Hepatocellular Cancer Progression.
    Yu Y; Chen X; Zhang W; Liu J
    Biomed Res Int; 2021; 2021():4051192. PubMed ID: 34957303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.